flecainide / Generic mfg. - LARVOL DELTA

Multimodal Management of Refractory Ventricular Tachycardia Due to Aconitine Poisoning: A Case Report in a Resource-Limited Setting. (PubMed, J Am Coll Emerg Physicians Open) - "In the absence of extracorporeal membrane oxygenation (ECMO), flecainide, or procainamide, a multimodal approach involving multiple antiarrhythmics, including amiodarone, phenytoin, and stellate ganglion block, ultimately restored normal sinus rhythm. This case underscores the importance of early recognition and a flexible, multimodal treatment strategy in managing aconitine-induced arrhythmias, especially in resource-limited settings."

Journal • Addiction (Opioid and Alcohol) • Cardiovascular • Ventricular Tachycardia

Catecholaminergic polymorphic ventricular tachycardia in children-incidence and trends in detection, presentation and management. (PubMed, Arch Dis Child) - "The rate of infants born who are later diagnosed with CPVT in childhood is approximately 1 in 65 000 live births. Suboptimal adherence and beta blocker therapy without flecainide appeared related to recurrent cardiac events."

Journal • Cardiovascular • Pediatrics • Ventricular Tachycardia

Severe Myocardial Involvement and Persistent Supraventricular Arrhythmia in a Premature Infant Due to Enterovirus Infection: Case Report and Literature Review. (PubMed, J Cardiovasc Dev Dis) - "Despite multi-agent regimen, including propranolol, flecainide, and amiodarone, the infant showed persistent junctional rhythm until seven months of age, later transitioning to atrial rhythm with stable cardiac function. EV infections may cause long-term cardiovascular comorbidities (such as left ventricular dysfunction or mitral valve regurgitation), necessitating continuous monitoring through echocardiography and ECG. Collaboration between neonatologists and pediatric cardiologists is crucial for effective treatment and follow-up."

Journal • Cardiovascular • CNS Disorders • Heart Failure • Infectious Disease • Inflammation • Pediatrics • Ventricular Tachycardia

Loss of atrial capture resulting in hemodynamic compromise in the context of flecainide and amiodarone administration with normal electrolyte function. (PubMed, HeartRhythm Case Rep) - No abstract available

Journal • Atrial Fibrillation • Cardiovascular

Long-term adherence to flecainide as a rhythm control therapy in recurrent atrial fibrillation - a retrospective cohort study. (PubMed, Scand Cardiovasc J) - "Rhythm-related adverse events were associated with RV-FAC, LAVI and moderate mitral regurgitation. ECG and echocardiographic indices were associated with discontinuation of flecainide, including safety and efficacy outcomes in long-term treated patients with AF."

Journal • Retrospective data • Atrial Fibrillation • Cardiovascular

Simultaneous optical recording of action potentials and calcium transients in cardiac single cells differentiated from type 1 CPVT-iPS cells. (PubMed, Front Physiol) - "In drug-loading experiments on CPVT1 (RyR2-I4587V) hiPSC-derived ventricular-like CMs, carvedilol and flecainide demonstrated some effectiveness, while JTV519 at 3 µM exhibited both efficacy and alterations in AP waveforms. The Ca2+/calmodulin-dependent serine-threonine protein kinase II (CaMKII) inhibitor KN-93 at 1 µM was highly effective (93%) at reducing Ca2+ transient abnormalities without altering AP waveforms."

Journal • Cardiovascular • Ventricular Tachycardia • CYP19A1 • PVT1

Flecainide toxicity and BRASH syndrome unmasking severe coronary artery disease: a diagnostic and management challenge (ESC-WCC 2025) - No abstract available

Cardiovascular • Coronary Artery Disease

Joint relevance of CYP2D6 and H558R in the efficacy and toxicity of flecainide in patients with atrial fibrillation: a cohort study. (ESC-WCC 2025) - No abstract available

Clinical • Atrial Fibrillation • Cardiovascular

Survival post out-of-hospital cardiac arrest from anomalous right coronary artery: A case report and insight into management. (PubMed, J Cardiol Cases) - "Other investigations, including flecainide challenge test, cardiac magnetic resonance imaging, and treadmill stress tests were unyielding...After appropriate surgical correction and with preserved cardiac function, an implantable cardiac defibrillator may not always be necessary. This decision should follow a detailed discussion between the cardiologist, cardiothoracic surgeons, and patient."

Journal • Cardiovascular

Flecainide Toxicity Leading to Transient Heart Failure With Reduced Ejection Fraction: A Case Study. (PubMed, Cureus) - "The proposed mechanism involves QRS prolongation and impaired myocardial conduction due to sodium channel blockade, compounded by transient renal dysfunction. Clinicians must remain vigilant for cardiotoxic effects of flecainide, especially in patients with evolving renal function, even in the absence of traditional contraindications."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Nephrology • Renal Disease

FLECA-ED: Flecainide Versus Amiodarone in the Cardioversion of Paroxysmal Atrial Fibrillation at the Emergency Department, in Patients With Coronary Artery Disease Without Residual Ischemia (clinicaltrials.gov) - P3 | N=80 | Recruiting | Sponsor: Hippocration General Hospital | N=200 ➔ 80 | Trial completion date: Nov 2024 ➔ Jan 2026 | Trial primary completion date: Oct 2024 ➔ Dec 2025

Enrollment change • Trial completion date • Trial primary completion date • Atrial Fibrillation • Cardiovascular • Coronary Artery Disease

Exploring Public Interest in Atrial Fibrillation and Its Treatment Measures: A Google Trends Analysis. (PubMed, Cureus) - " This study demonstrates a rising public interest in AF. Searches related to medications such as amiodarone, metoprolol, diltiazem, and flecainide, as well as procedures including cardioversion, artificial cardiac pacemaker, and left atrial appendage occlusion, have all shown increasing trends."

Journal • Atrial Fibrillation • Cardiovascular • Respiratory Syncytial Virus Infections

Selectivity filter mutation in Na V 1.5 promotes ventricular tachycardia. (PubMed, bioRxiv) - "Therefore, we generated mice heterozygous for Na V 1.5-DE E A. Cardiomyocytes isolated from DE E A hearts exhibited substantial reduction in sodium current, ventricular conduction slowing and susceptibility to ventricular arrhythmias in vivo that were unmasked by flecainide. Together, DE E A murine model is the first to recapitulate a functional deficiency in Na V 1.5, and thus offers insight into the proarrhythmic mechanism of BrS."

Journal • Cardiovascular • Genetic Disorders • Ventricular Tachycardia

NaV1.5 or KCa2 channel blockade does not increase arrhythmia risk in hypokalemic rabbit hearts, unlike KV11.1 inhibition with dofetilide. (PubMed, Int J Cardiol Heart Vasc) - "Neither of the KCa2 channel inhibitors (AP14145 or AP30663) or flecainide (NaV1.5 inhibitor) prolonged ventricular action potential duration (APD90) or increased pro-arrhythmic markers, whereas dofetilide (KV11.1 blocker) prolonged APD and increased the susceptibility to ventricular arrhythmia. These findings suggests that KCa2 channels have minimal importance for ventricular repolarization in healthy rabbit hearts under both normo- and hypokalemic conditions."

Journal • Preclinical • Atrial Fibrillation • Cardiovascular • NAV1

Flecainide Toxicity in a Patient with a Pacemaker. (PubMed, Rev Port Cardiol) - No abstract available

Journal

Predicting the Outcomes of External Direct Current Cardioversion for Atrial Fibrillation: A Narrative Review of Current Evidence. (PubMed, J Cardiovasc Dev Dis) - "Biphasic waveforms and antiarrhythmic drugs, such as amiodarone and flecainide, improved cardioversion success. Integrating these parameters into clinical practice can guide individualised patient management and improve outcomes. Further research is needed to validate these predictors and enhance precision medicine approaches in DCCV."

Biomarker • Journal • Review • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Fibrosis • Genetic Disorders • Heart Failure • Immunology • Inflammation • Obesity • CRP

Successful Treatment of a Case of Flecainide-induced Ventricular Tachycardia Secondary to Acute Kidney Injury (ATS 2025) - "His past medical history is significant for atrial fibrillation (on flecainide and apixaban) and his last echocardiography (echo) was unremarkable. Flecainide should be suspended in patients with AKI to avoid toxicity. Flecainide-induced VT could be successfully treated with cardioversion."

Clinical • Acute Kidney Injury • Atrial Fibrillation • Cardiovascular • Metabolic Disorders • Nephrology • Renal Disease • Ventricular Tachycardia

Flecainide-Induced Right-sided Cardiogenic Shock (ATS 2025) - "The patient was discharged on hospital day 10 after initiation of goal directed medical therapy, as well as sotalol to manage his arrhythmia. There is no guideline-supported treatment of flecainide toxicity, thus early discontinuation and aggressive hemodynamic support are the mainstays of therapy. A flecainide level may take days to weeks to result, owing to the importance of early consideration of this potential etiology of shock."

Atrial Fibrillation • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Heart Failure • Hypertension • Nephrology • Renal Disease

The maternal exposure of digoxin and flecainide in relation to the safety and effectiveness in the treatment of non hydropic fetal tachycardia. (PubMed, Heart Rhythm) - "Digoxin monotherapy successfully treated fetal tachycardia in only 32% of cases. Adding flecainide improved response to 93%, although it increased side effects, which could be managed with dose reductions. Maternal digoxin levels were stable throughout pregnancy."

Journal • Cardiovascular

Failed Pacemaker Detection of Flecainide-Induced Atrial Flutter With One-to-One Atrioventricular Conduction. (PubMed, JACC Case Rep) - "Flecainide therapy has been well-described to organize AF into AFL that is predisposed to 1:1 AV conduction. This case underscores a concerning limitation in the detection of potentially life-threatening arrhythmias with some nominal pacemaker devices."

Journal • Atrial Fibrillation • Cardiovascular

Catecholaminergic Polymorphic Ventricular Tachycardia in a 16-year-old: Case Report. (PubMed, Clin Pract Cases Emerg Med) - "Catecholaminergic polymorphic ventricular tachycardia is a rare genetic disease with significant morbidity and mortality. Treatment decisions for acute CPVT often occur without prior knowledge of the disease; so, in patients diagnosed with CPVT, physicians should implement appropriate therapeutic options to prevent future cardiac events. For patients who remain symptomatic despite compliance with beta blockers and/or other antiarrhythmic therapy, interventions such as placement of an implantable cardioverter defibrillator or sympathetic denervation may be necessary to prevent life-threatening arrhythmias. This case also underscores the importance of obtaining a detailed family history and coordinating care with other physicians in cases where history is limited."

Journal • Cardiovascular • CNS Disorders • Genetic Disorders • Pediatrics • Ventricular Tachycardia

Advancing Cardiovascular Drug discovery with iPSC-Derived 3D Cardiac Microtissues in High-Throughput Screening (ASGCT 2025) - "In modelling catecholaminergic polymorphic ventricular tachycardia (CPVT), arrhythmias were observed that could be rescued by flecainide, validating their use in drug testing...The results highlight their potential to bridge the gap between in vitro and in vivo systems, improving the accuracy of preclinical evaluations and accelerating the development of novel cardiovascular therapies. Disease Focus of Abstract:Cardiovascular/Heart Disease"

Cardiovascular • Heart Failure • Reperfusion Injury • Ventricular Tachycardia

Case Report: High efficacy of low-dose flecainide as an add-on therapy to a beta-blocker for treating a high burden of idiopathic ventricular arrhythmias in a juvenile athlete. (PubMed, Front Cardiovasc Med) - "Initiation of treatment with atenolol 12.5 mg twice a day led to inadequate reduction of PVCs, with 29,452 isolated monomorphic PVCs (PVC burden: 29%) still observed on 24-h ambulatory electrocardiographic monitoring. The optimization of drug treatment was favored over catheter ablation since the athlete was a child and the probable origin of PVCs was the left ventricular outflow tract. This case report highlights that flecainide at a relatively low dose as an add-on therapy to a beta-blocker was highly effective and safe for treating high-burden PVCs originating from the ventricular outflow tract in a juvenile athlete."

Journal • Cardiomyopathy • Cardiovascular

PALLIATE-AF: Pacing of Left Bundle Branch Area and Atroventricular Node ablatIon in Patients With Symptomatic Atrial Fibrillation (clinicaltrials.gov) - P=N/A | N=50 | Recruiting | Sponsor: Seoul National University Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Atrial Fibrillation • Cardiovascular

Flecainide for the Treatment of Andersen-Tawil Syndrome. (PubMed, JACC Clin Electrophysiol) - "These data demonstrate that flecainide treatment may be effective and well-tolerated in ATS1 patients. The occurrence of an arrhythmic storm in 1 patient underscores the potential for toxicity and mandates careful dose titration monitored by rest and exercise electrocardiogram for QRS widening."

Journal • Cardiovascular • Ventricular Tachycardia